Midgard, Håvard, Hajarizadeh, Behzad, Hellard, Margaret, Robaeys, Geert, Thurnheer, Marcia C., Weltman, Martin, Amin, Janaki, Marks, Philippa S., Quiene, Sophie, Dore, Gregory J., Dalgard, Olav, Grebely, Jason, Cunningham, Evan B., Conway, Brian, Backmund, Markus, Bruggmann, Philip, Bruneau, Julie, Bourgeois, Stefan, Dunlop, Adrian, Foster, Graham R.. Elsevier; 2017. Changes in risk behaviours during and following treatment for hepatitis C virus infection among people who inject drugs: the ACTIVATE study.

Cunningham, Evan B., Hajarizadeh, Behzad, Swan, Tracy, Marks, Philippa S., Quiene, Sophie, Applegate, Tanya L., Weltman, Martin, Shaw, David, Dunlop, Adrian, Bruneau, Julie, Midgard, Håvard, Bourgeois, Stefan, Dalgard, Olav, Thurnheer, Maria Christine, Dore, Gregory J., Grebely, Jason, Amin, Janaki, Hellard, Margaret, Foster, Graham R., Bruggmann, Philip, Conway, Brian, Backmund, Markus, Robaeys, Geert. BioMed Central; 2017. Adherence to response-guided pegylated interferon and ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: the ACTIVATE study.

Grebely, Jason, Dalgard, Olav, Amin, Janaki, Marks, Philippa S., Quiene, Sophie, Applegate, Tanya L., Weltman, Martin, Shaw, David, Dunlop, Adrian, Hellard, Margaret, Bruneau, Julie, Midgard, Håvard, Cunningham, Evan B., , , , Hajarizadeh, Behzad, Foster, Graham R., Bruggmann, Philip, Conway, Brian, Backmund, Markus, Robaeys, Geert, Swan, Tracy. Elsevier; 2017. Efficacy of response-guided directly observed pegylated interferon and self-administered ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: the ACTIVATE study.